Dimitra Mougiou

Mrs. Dimitra Mougiou


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
DMDimitra Mougiou
Dimitra Mougiou
Georgia GioulaGeorgia Gioula
Georgia Gioula
Lemonia SkouraLemonia Skoura
Lemonia Skoura
Cleo AnastassopoulouCleo Anastassopoulou
Cleo Anastassopoulou
Melania KachrimanidouMelania Kachrimanidou
Melania Kachrimanidou
Clostridioides difficile (C. difficile) is a significant healthcare-associated pathogen that is predominantly caused by antibiotic-induced microbiota disturbance. Antibiotics decrease microbial diversity, resulting in C. difficile colonization and infection. Clostridium difficile infection (CDI) manifests through toxins A and B, causing diarrhea and colitis. Antibiotic usage, old age, and hospitalization are significant risk factors. A healthy gut microbiota, which is dominated by Firmicutes and Bacteroidetes, provides colonization resistance to C. difficile due to competition for nutrients, creating inhibitory substances and stimulating the immune response. Antibiotic-induced dysbiosis decreases resistance, allowing C. difficile spores to transform into vegetative forms. Patients with CDI have decreased gut microbiota diversity, with a decrease in beneficial bacteria, including Bacteroidetes, Prevotella, and Bifidobacterium, and a rise in harmful bacteria like Clostridioides and Lactobacillus. This disparity worsens the infection’s symptoms and complicates therapy. Fecal Microbiota Transplantation (FMT) has emerged as a potential therapy for recurrent CDI by restoring gut microbiota diversity and function. Comprehending the connection between gut microbiota and CDI pathogenesis is critical for establishing effective preventive and treatment plans. Maintaining a healthy gut microbiota through careful antibiotic use and therapeutic options such as FMT can help in the management and prevention of CDI.

3 March 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
DMDimitra Mougiou
Dimitra Mougiou
Georgia GioulaGeorgia Gioula
Georgia Gioula
Lemonia SkouraLemonia Skoura
Lemonia Skoura
FMFani Minti
Fani Minti
Theodoros KarampatakisTheodoros Karampatakis
Theodoros Karampatakis
Melania KachrimanidouMelania Kachrimanidou
Melania Kachrimanidou
Background/Objectives: The gut microbiome plays an important role in the colonization of an individual by Clostridioides difficile and in the development of Clostridioides difficile infection (CDI). The main purpose of this study was to compare the gut microbiomes of patients with CDI and healthy individuals. Methods: We prospectively included 48 individuals: 32 patients with CDI and 16 healthy individuals. Microbiomes were analyzed by sequencing the hypervariable regions of the 16S rRNA gene using an Ion GeneStudio™ S5 System. Further statistical analysis of microbiome data was performed with the open-source programming language R version 3.5.2. Results: Among the CDI patients, Firmicutes and Proteobacteria were the most abundant phyla, while Enterobacteriaceae and Enterococcaceae were the most abundant families. Genus-level analysis showed that Enterococcus was the dominant genus in CDI patients; in contrast, in healthy individuals, Faecalibacterium was the most abundant. The MaAsLin2 tool revealed that members of the family Enterococcaceae and the genus Enterococcus were more abundant in patients with CDI than in healthy individuals. Alpha and beta diversity did not reveal differences between the two study groups. Conclusions: We observed differences in microbiome patterns between healthy individuals and CDI patients that were consistent with the literature. Further studies are needed.